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Medicines Regulation in West Africa: Current State and Opportu-
nities
O. Sopein-Mann1, Z. Ekeocha2, S. Byrn3, K. Clase4 
ABSTRACT
Ndomondo-Sigonda et al. (2017) observed that there is scarcity of information on human resources (personnel
devoted to regulation of medicines) in the domain of medicines regulation in the sub-Saharan Africa (SSA). The
published information on medicines regulation by the National Medicines Regulatory Authorities (NMRAs) in the
Economic Community of West African States (ECOWAS) region are no longer current and consistent with the
current realities in the NMRAs. In order to reveal this occurrence, show the trends that exist over the years and
make appropriate recommendations, data were collected and compared from 2005, 2010 and 2017 research re-
ports on seven regulatory features of the fifteen Members States of ECOWAS. The results show that there was
missing information per regulatory feature and country. There was also an overall increasing trend in the number
of NMRAs in the region that showed progress with respect to the measured regulatory features - Autonomy (Au-
thority and Legal form), Marketing Authorization), GMP inspection, Quality Control, Quality Management System,
Information Management System and Harmonization and International cooperation. People of Africa have a valu-
able story to tell as it relates to medicines regulation. This report is written by a West African from the perspective
of a West African involved in the study and practice of medicines regulation by the NMRAs in the ECOWAS.
Keywords: medicines, regulation, marketing authorization, Good Manufacturing Practice (GMP), National Medi-
cines Regulatory Authorities (NMRAs); Economic Community of West African States (ECOWAS), West African
Health Organization (WAHO), West African Medicines Regulatory Harmonization (WA-MRH)
1. INTRODUCTION
Early History on the Basis of Medicines Regula-
tion
Griffin (2004) narrates the history of the foundation of
modern medicines regulation, which started with
Mythridatum and the related product Theriac as the
universal panacea in the second century BC and first
century AD, respectively. These two products were
thought to be effective for all illnesses, but if they did
not work as expected, bad quality ingredients and
poor manufacturing were blamed. This, then, called
for the need to ensure quality of the ingredients, es-
tablish standard formulation for these products and
ensure competence of the manufacturers.
For this reason, Mythridatium and Theriac were pro-
duced in the public space as it was generally accepted
that failure was due to the probable misdemeanor of
the manufacturers (pharmacists) (Griffin, 2004). How-
ever, in 1745, doubts arose regarding their efficacy
and safety due to possible interactions among the in-
gredients used. By 1746, the products were removed
from London Pharmacopoeia; and in 1799, a decree
was enacted to convene a group of elite physicians
who examined all products before they were released
to the public.
From 1540, one of the earliest laws on drug control
was established, which permitted the inspection of the
premises and wares of the apothecaries; and to bring
upon them appropriate sanctions if found guilty of
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2
non-compliance (Griffin, (2004). The statute specifi-
cally permitted the appointment of inspectors, inspec-
tion of the apothecaries’ stores, destruction of defec-
tive and corrupt wares and drugs not suitable for hu-
man consumption and charging of higher fees when
inspections were excused or refused.
In order to control the quality and standard of mythri-
datium and theriac, an official and obligatory docu-
ment was produced called pharmacopoeia, derived
from two Greek words, pharmakon (drugs) and poiia
(making). The first pharmacopoeia in Europe was
published for the apothecaries in Florence in 1498
and, subsequently, in other cities such as Barcelona
in 1535, Nuremberg in 1546 and London
(pharmacopoeia Londinensis) in 1618 (Griffin, 2004).
The Pharmacopoeia helped establish the standard
formulation of mythridatium and theriac which made
inspection easier and lifted the limit of the manufac-
ture of the products by one apothecary. During the
London plague of 1650, three apothecaries were ap-
proved to manufacture mythridatium and theriac in
London (Griffin, 2004).
The Food and Drug Legislation came into existence
in 1872 and eradicated all of the existing laws and
statutes which had allowed the Censors of the Col-
lege of Physicians and Wardens of the Worshipful So-
ciety of Apothecaries to carry out their activities to
serve as the basis of modern day medicines regula-
tion (Griffin, 2004). Mythridatium and Theriac were the
motivation for medicines regulation, being the first
medicines to be challenged on the bases of efficacy
and drug interaction (Griffin, 2004).
Griffin (2004) also stated that the Medical and Physi-
cal Journal, in 1799, proposed that no product should
be advertised and sold to the public without the exam-
ination, analysis and declaration of quality by the col-
lege of physicians. This is 170 years before the Med-
icines Act of 1968 in the United States of America.
Rago and Santoso (2008), cited that the history of reg-
ulation of medicines dated as far back as 1540 and
the history of pharmacopeia in Europe can be traced
to the 16th century. However, the accelerated evolu-
tion of regulation of medicines came about by some
unfortunate events, such as the poisoning by diethy-
lene glycol, where hundreds lost their lives after taking
the contaminated mixture and the thalidomide
disaster in Europe, where thousands of babies were
born deformed, (Rago & Santoso, 2008). After the
Thalidomide disaster, several directives (65/65/EEC),
laws, regulations and administrative actions arose.
Acts in Europe and in the United States of America on
regulation of medicines, requirements on current
Good Manufacturing Practices (CGMP) and official
registration of drug establishments in the USA also
came into existence (Rago & Santoso, 2008).
1930 - United States Food and Drug Administra-
tion (USFDA)The history of medicines regulation in
the United States of America is similar to the UK and
Europe. An event in 1906 led to a law which prohib-
ited misbranded and adulterated foods, drinks and
drugs in interstate commerce. The law was enforced
by the Bureau of Chemistry in the Department of Ag-
riculture, which later became the Food and Drug Ad-
ministration in 1930. In 1938 the Federal Food, Drug
and Cosmetic (FD&C) Act created new provisions for
manufacturers to demonstrate that a drug was safe
before it could be marketed (USFDA, n.d.). The laws
of the United States of America were improved, as
occasions demanded. The latest law came in 2003,
when an authority under the Pediatric Research Eq-
uity Act was granted to the FDA to require sponsors
to conduct clinical research for new drugs in pediat-
ric drug applications (USFDA, n.d.).
Ten years after the Council Directive 65/65/EEC in
Europe, the idea of harmonization was introduced.
The Mutual Recognition Procedure began in 1975
and the Central Procedure, in 1987, to ensure a com-
mon market for medicines in Europe (Rago & San-
toso, 2008).
Simultaneously, harmonization was expanding be-
yond Europe. Collaboration started during a discus-
sion among officials from Japan, the European Union
and the United States of America during the Interna-
tional Conference of Drug Regulatory Authorities
(ICDRA), organized by the World Health Organization
(WHO) in 1989. These discussions established the In-
ternational Conference on Harmonization of Tech-
nical Requirements for Registration of Pharmaceuti-
cals for Human Use (ICH) in Paris in 1990 (Rago &
Santoso, 2008), where dossiers of new and innova-
tive medicines would be evaluated to ensure quick ac-
cess to the people who needed them most.
Since it is mostly generic medicines that flood many
low- and medium-income countries (LMIC), the World
Health Organization (WHO) played a supportive role
in national, regional, inter-regional and international
harmonization to ensure a fast-reaching, international
consensus on quality, safety and efficacy standards
in order to accelerate entry into the market of quality
new and generic medicines.
2003 – The Establishment of the UK Medicines
and Healthcare Products Regulatory Agency
(MHRA)
According to Breckenridge (2004), the Medicines and
Healthcare Products Regulatory Agency (MHRA) was
established in the United Kingdom by the merger of
the Medicines Control Agency (MCA), which was in
 
        
      
        
           
       
        
        
       
          
      
        
      
         
        
       
        
         
       
     
         
       
    
        
        
       
        
          
        
       
         
         
          
       
  
        
       
      
      
       
     
        
        
        
       
          
        
        
       
 
      
         
         
    
          
        
       
        
        
         
      
        
      
 
       
      
      
      
     
        
     
       
        
        
       
     
        
          
         
     
        
         
          
       
      
   
 
         
     
     
       
        
       
        
      
        
       
      
     
      
  
     
  
       
    
      
  
         
      
      
3
charge of the medicines regulation, and the Medical
Devices Agency (MDA), which regulated and con-
trolled the Medical Devices. This merger forced the
UK to join the League of Nations with the USA and
Europe, where both medicines and medical devices
are housed under one organization. The functions of
the two erstwhile Agencies (MCA and MDA), became
the scientific and organizational reasons behind the
formation of MHRA in the UK as well as highlighted
the possible challenges it would face.
Some of the organizational challenges, faced by the
MHRA, mentioned by Breckenridge (2004), were
premised on the co-location of the two agencies, as
they were located in different sites. Co-location was
necessary to unify an organization, to ensure compat-
ibility of the Information Technology (IT) systems of
the two organizations and to address the cultural and
scientific challenges of bringing together large and
small organizations with different backgrounds. Addi-
tional challenges were the need for MHRA to ensure
a proactive and effective communication with both
stakeholders (patients, healthcare professionals, in-
dustries and government) and staff. There was the
need to work more closely with other newly estab-
lished agencies in the UK, whose responsibilities con-
siderably overlap with MHRA. As new countries joined
the EU, the need grew for MHRA to provide support
for the then London-based EMEA. The EMEA helped
new countries build their regulatory medicines and
medical devices capacities. It also worked with the EU
to ensure that a uniform standard of approval existed
across Europe for the new Notified Bodies in the EU
that approved medical devices for UK market
(Breckenridge, 2004).
The scientific challenges MHRA faced at that time
were: tissue engineering and its regulation, which re-
quire the combination of human-derived cells; me-
chanical support and molecular signaling processes
(pharmacology and medical devices) for the treatment
of individual patients; pharmacogenetics in medi-
cines. In addition, MHRA faced the challenge of in-
creased pressure to have a high percentage of ad-
verse reaction reports in its database, while carrying
out exhaustive and effective Post Market Surveillance
(PMS) in order to ensure patient safety. The MCA had
been criticized for not having exhaustive listings of ad-
verse reactions. MHRA now strives to capture quality
rather than quantity of adverse reaction reports.
2005 - Medicines Regulation in Africa
The first plan ‘Mother plan’ for medicines regulation in
Africa was developed in 2005 during the 1st African
Medicines Regulatory Authorities Conference (AM-
RAC) that was held in Addis Ababa, Ethiopia and was
documented as a WHO/AFRO’s final report of the
medicines regulation cross-sectional view in Africa in
2005. It became the Strategic Plan from 2006-2010,
which identified the existing problems of regulation of
medicines in 2005 in Africa. It also suggested the stra-
tegic approach/interventions and activities needed to
be implemented in order to facilitate the required
growth of medicines regulation in Africa.
The regulatory landscape was characterized by the
following, among others: ineffective licensing system,
weak product registration, poor inspection practices,
inadequate access to quality control laboratories, in-
adequate market control, non-existence of pharma-
covigilance and control of promotion, lack of clinical
trials oversight, inadequate communication and infor-
mation exchange system, lack of transparency and
accountability and conflict of interest. According to the
final report, of the 46 sub-Saharan African countries,
7% of the National Medicines Regulatory Authorities
(NMRA) had moderately developed medicine regula-
tory capacity, 63% had minimal capacities, while 30%
did not have an NMRA in place. These problems were
not improving much despite the efforts of WHO, or
other international organizations and donor communi-
ties, because of the absence of government support,
lack of adequate number of trained and qualified staff,
high staff turn-over due to low salaries and lack of in-
centives, inadequate and unsustainable funding of the
NMRAs and weak infrastructure (World Health Organ-
isation, 2005).
In order to solve the problems, the 1st African Medi-
cines Regulatory Authorities Conference (AMRAC)
convened representatives from the National Medi-
cines Agencies, regional blocks in the sub-Sahara Af-
rica and members of harmonization initiatives such as
ICH, CEAC and SADC. After extensive presentation
of the situation and group discussion, the group doc-
umented the strength, probable weakness and rec-
ommendations, which led to a five-year plan towards
improving the scenario. Some of the weaknesses
highlighted during the meeting were:
• weak Medicines Regulatory Authorities
(MRAs) with limited human and financial re-
sources;
• parallel and overlapping harmonization initia-
tives;
• lack of structures to coordinate harmonization
initiatives, e.g. secretariat;
• inadequate exchange of information and ex-
periences;
• lack of a common understanding of the true
meaning and vision/goals of harmonization;
• lack of political commitment;
 
       
     
       
  
       
    
       
         
         
      
     
     
    
    
    
 
 
       
     
 
        
       
       
          
      
      
      
          
       
       
         
       
       
         
       
       
         
        
     
 
        
          
       
       
       
       
      
       
      
       
 
     
        
      
        
        
         
         
    
         
      
    
     
        
      
     
      
      
         
       
      
        
   
         
    
      
      
 
     
     
    
    
   
       
     
 
      
   
         
        
         
           
       
       
       
         
        
         
   
4
• lack of commitment from MRAs;
• lack of sustainable funding.
The recommended steps to carry out harmonization
were:
• build trust and commitment among technical
people towards harmonization;
• secure political commitment and support;
• carry out situation analysis and identify gaps;
• define the vision and goals of harmonization;
• set up administrative structures/secretariat;
• develop common strategies;




2008: A Call for More Effective Regulatory Sys-
tem in Nigeria, West Africa
Akuse et al. (2012) reported the unfortunate incident
which occurred in Nigeria between October and No-
vember 2008, where children suffered Acute Kidney
Injury (AKI), and eventually died, due to ingestion of a
particular type of “teething mixture” containing para-
cetamol and diphenhydramine that was contaminated
with Diethylene Glycol (DEG). Similar incidents oc-
curred in Nigeria in 1999 and in other countries, such
as Bangladesh, India, Haiti, Panama, South Africa
and the United States of America.
Akuse et al. (2012) carried out a multicenter study
where information from hospital records was obtained
to review the clinicopathological features of all chil-
dren with AKI over a six-month period. The study fo-
cused on discovering other means of promptly diag-
nosing and differentiating children who had Acute Kid-
ney Injury (AKI) due to ingestion of Diethylene Glycol
(DEG) from those who did not in a resource-con-
strained environment such as Nigeria.
The results of the study showed that differentiating
AKI caused by ingestion of DEG was difficult, and that
obtaining detailed drug intake history and improved
facilities for hemodialysis for infants, among others,
would assist such differentiation. The authors affirmed
that prevention of future occurrences would require
improved manufacturing practices, effective field drug
testing and international monitoring of raw materials
imported for pharmaceutical manufacturing, which are
all necessary for effective regulatory systems and
structures.
2009-2010, the World Health Organization
The World Health Organization (WHO) carried out a
rapid assessment in 2009-2010 which provided in-
sights into the state of medicines regulation in sub-
Saharan Africa. The assessment was done on 26
countries: eleven in the East Africa, eight in West Af-
rica, two from South Africa and five countries from
Central Africa (WHO, 2010).
The study measured nine core regulatory functions of
National Medicines Regulatory Authorities against the
background of each countries geographical, socio-
economic and pharmaceutical indicators (WHO,
2010). The nine functions that were assessed were
the structure and implementation of regulatory func-
tion, marketing authorization, licensing activities,
import control, inspections, quality control, market
surveillance and control of clinical trials.
In each of these core regulatory functions, several sub
components were examined. For example, under the
assessment of the Marketing Authorization, the fol-
lowing components were assessed in order to identify
the gaps:
• the existence of the legal basis to authorize
medicines for the market;
• existence of guidance for applicants;
• standard operating procedures (SOPs) for
assessment;
• existence of advisory committee;
• existence of external assessors;
• full time assessors;
• Secure filing space;
• computerized system;
• existence of list of approved products includ-
ing Summary of Products Characteristics
(SmPC);
• recognition of stringent regulatory authorities’
decisions (WHO, 2010).
According to the report (WHO, 2010), 55% of the
eleven countries studies in Eastern Africa had existing
legal basis, 27% had inadequate legal basis, and the
remaining 9% did not have a legal basis to carry out
marketing authorization of medicines. Only 9% had
detailed guidance for applicants with respect to infor-
mation on format and content of submission require-
ments. 36% had no SOP for assessment of medicines
dossiers, 9% had written SOPs, while the remaining
countries had SOPs that were either not adequate or
very limited.
 
       
        
      
         
     
         
        
        
        
        
        
           
          
        
          
       
          
     
        
       
        
        
         
          
       
          
       
        
         
     
         
        
         
  
       
  
       
      
        
        
 
         
 
      
      
          
    
          
  
           
      
  
     
 
        
        
         
      
         
       
        
        
      
           
          
         
       
     
        
          
      
        
        
       
        
       
       
        
         
         
      
         
        
           
         
      
     
 
     
        
        
     
         
      
        
        
          
       
       
          
       
        
       
5
Regarding the existence of the Advisory Committee
for Marketing Authorization, 27% of the East African
countries had an operational advisory committee,
where 45% had an advisory committee that was either
non-operational or non-existent. Advisory committees
of the remaining countries were either just a technical
committee without the correct expertise and did not
have the capacity to review the medicines dossiers.
With respect to the existence of external assessors,
45% had no external assessors, 18% had external as-
sessors, while 27% either had no external assessors
due to lack of funding, or they were limited in capacity.
As per the existence of full-time assessors, 82% of the
countries had an insufficient number. With respect to
secure filing space, it was inadequate in 91% of the
countries. With respect to existence of a computer-
ized system, 36% had none, 55% had either the WHO
Model System for Computer-assisted Drug Registra-
tion (SIAMED) in combination with other databases or
stand-alone databases, while 9% had not established
a regulatory system. Regarding the list of approved
products, including SmPC, 91% of the countries had
this list in their systems, but were not updated, pub-
lished and did not include the SmPC. 9% of the coun-
tries were marked ‘not applicable’ because their reg-
ulatory system did not exist. 45% of the countries did
not recognize decisions of stringent regulatory NRAs.
9% recognized the decisions of US-FDA, WHO PQ
and EU, while 18% either required or reviewed the
Certificate of Pharmaceutical Product (CPP).
The report (WHO, 2010) also had information on how
the eight countries in West Africa fared:
• 50% had adequate legal basis to carry out
marketing authorization.
• 100% had inadequate guidance for the appli-
cants.
• 100% had inadequate SOPs for assessment.
• 75% had an Advisory Committee.
• 88% of the countries had external assessors.
• All of the countries had insufficient full-time
assessors.
• All of them also had inadequate secure filing
space.
• 88% had SIAMED and/or internally net-
worked database or standalone Excel sheets.
• 75% had a list of approved products, but were
not published or updated.
• None had the SmPC attached to the list of ap-
proved products.
• 63% of the countries did not have a system of
recognition of the decision of stringent regu-
latory authorities.
• 13% requested the CPP.
In Southern Africa, where only two countries were as-
sessed, both had adequate legal basis, one had ade-
quate guidance for applicants, the other had no SOP
for assessment. Both countries had Expert Commit-
tee or the Advisory Committee, both of the countries
had adequate qualified external assessors but the full-
time assessors were insufficient. Only one of the
countries had secured filing space and a standalone
database instead of the required computerized sys-
tem of filing. In regards to the list of approved products
with SPC, both had a list either outdated or without
the SPC and both of the countries either recognized
the decision of stringent regulatory authorities or re-
quested decisions from other NMRAs.
In Central Africa, five countries were assessed. 60%
of the countries had adequate legal basis to carry out
Marketing Authorization; 20% had outdated and un-
detailed guidance for the applicant, 20% had no
guidance. 60% had no SOPs for assessment, 20%
had validated SOPs, while 20% had inadequate
SOPs, with only administrative documents. In 80% of
the countries, an advisory committee existed either
unofficially or not specific to Market Authorization.
60% had no external assessors and 80% had insuffi-
cient full-time assessors. None of the five had an ad-
equately secured filing space and only 40% had the
computerized system called SIAMED. The remaining
countries had none or other types, which are not opti-
mal. Regarding the list of approved products, which
included the SPC, only 20% had the list but did not
include the SPC. In respect to the countries that rec-
ognize decisions of stringent regulatory authorities,
only 40% requested the CPP.
2014, World Health Assembly 67.20
On May 24, 2014, the sixty-seventh World Health As-
sembly (WHA 67.20), Agenda 15.6, which was on
Regulatory System Strengthening for medical prod-
ucts, related with the 2005 Mother Plan on medicines
regulation. The highlights and recommendations of
the resolution were geared towards the various roles
that WHO/AFRO and WHO international could play to
fulfill the elements of the plan, which only they could
fulfill. The resolution highlighted certain points which
accentuated the stance of the World Health Organiza-
tion to play a pivotal role in support of the establish-
ment and sustainability of an effective regulatory sys-
tem in developing countries to ensure quality, safe
and efficacious medical products that will strengthen
 
       
 
      
      
        
       
        
       
        
        
        
      
         
        
       
       
       
   
       
      
         
         
   
        
    
        
       
    
 
        
     
       
    
   
       
        
       
 
 
      
    
 
     
         
         
      
        
          
         
        
         
        
      
       
      
        
 
      
      
    
    
       
   
       
      
     
          
         
        
       
        
      
     
         
       
       
         
      
        
       
             
    
 
      
    
       
       
      
       
      
         
           
        
      
      
     
       
      
           
      
        
     
       
       
         
         
6
the health systems and outcomes (WHO, 2015).
The resolution linked effective regulation to imple-
mentation of universal health coverage, achievement
of the Millennium Development Goals 4, reduction of
child Mortality, goal 5, Improvement of maternal
health) and goal 6, Combating HIV/AID, malaria and
other diseases. These goals are now Sustainable De-
velopment Goal (SDG) 3 (WHO, 2015) (UNDP, n.d.).
The resolution also linked effective regulation to the
impact of compromised quality, safety and efficacy of
medical products on treatment failure, drug re-
sistance, death and reduction of public trust on the
health system. The role of WHO’s prequalification to
procurement, contributions of the investment of good
proportion of national budgets, and global initiatives
on quality, safe and efficacious medicines were men-
tioned (WHO, 2015).
Concluding the World Health Assembly (WHA) 67.20
Resolution, the recommendations to Members State,
WHO and other stakeholders were in favour of the ful-
filment of the 2005 Strategic Plan. Some of the rec-
ommendations included:
• assessment of regulatory capacity of the NMRAs
using WHO benchmarking tools;
• collaboration of the national NMRAs to form re-
gional blocs that will move towards regulatory
convergence and transparency in decision-mak-
ing;
• development of strong legal basis and political di-
rection to support regulatory systems;
• pooling together of resources, regulatory experts,
adopting/adapting already developed technical
guidelines and guidance;
• strengthening of regulatory system as a compo-
nent of expansion of local and regional production
of quality, safe and efficacious medicines (WHO,
2015).
2018 Report of IGAD – Inter-Governmental Au-
thority on Development
The Inter-Governmental Authority on Development
(IGAD) is one of the Regional Economic Blocs (REC)
in Africa, situated in the horn of Africa comprising
Djibouti, Ethiopia, Eritrea, Kenya, Somalia, Sudan,
South Sudan and Uganda (Adan & Toroitich, 2018).
With respect to the Strategic Plan of the AMRAC in
2005, IGAD seems to have made progress in some
areas of medicines regulation, but due to challenges
highlighted by Adan and Toroitich (2018), there is still
much to be done. Some achievements that were men-
tioned include but not limited to:
• IGAD Member States working together to estab-
lish regional cross-border health policies and sec-
tor specific strategies on RMNCHN, MRH, TB and
HIV;
• MRH Workplan for 2019,
• established Technical Working Groups on Medi-
cines, Pharmacovigilance and Information Man-
agement System (IMS),
• prepared draft technical documents on IGAD dos-
sier submission,
• IGAD Marketing Authorization, procedure of Joint
Assessment of medicines dossier in IGAD’s re-
gion and Quality Guidelines.
From the report of Adan and Toroitich (2018), as in
other RECs in Africa, the level of medicines regulation
in IGAD seemed to be characterized with varied reg-
ulatory capacity in the Member States, where medi-
cines regulation was still domiciled in a department
under the Ministry of Health (non-autonomous
NMRAs). WHO Collaborative Registration Procedure
(CRP) was functional in some countries in the region.
Junior assessors were trained on medicines dossier
assessment. According to Adan and Toroitich (2018),
IGAD was not able to implement their MRH activities
due to challenges which included inadequate tech-
nical and human resources funds. Adan and Toroitich
(2018) solicited for equal strengthening and handling
of the RECs in Africa in order to fulfill the vision of the
AMRH program and AMA.
Industry Perspective of East African Community
(EAC) MRH in 2019
After 2005, the SSA countries started earnestly imple-
menting the recommendations from the AMRAC and,
by 2009, the African Medicines Regulatory Harmoni-
zation (AMRH) agreed to develop regional platforms
with harmonized regulatory procedures for the regis-
tration of medicines. EAC region started first in 2012
and six years later, by 2018, a study by Storehagen et
al. (2019) was conducted to evaluate the industrial
perceptions of medicines regulatory harmonization in
the East African Community (EAC).
The pharmaceutical industry, though favourably dis-
posed to the medicines regulatory harmonization, still
had their reservations regarding the harmonization in-
itiative because of the length of time it took to receive
the actual marketing authorization. The challenges in-
cluded getting all EAC countries to recognize EAC ap-
provals, unexpectedly higher quality standards com-
pared to national procedures, smaller, less attractive
markets not appealing from a corporate perspective
and the absence of free trade of pharmaceuticals in
the EAC region despite the existing EAC Free Trade
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Agreement, which officially launched the free move-
ment of goods and services in 2010.
The Storehagen study was a semi-structured inter-
view with document reviews. The main target group
for the interviews was pharmaceutical companies
(18 companies, including 64% of the total companies
who had experienced the EAC joint product assess-
ment procedure, and two EAC-based national medi-
cines regulatory authorities). Although harmonization
had been thought to be one of the solutions to mod-
ern regulation, the study showed that harmonization
must be handled appropriately with all factors cor-
rectly mixed before success can be achieved. The
method used in the study was effectively able to as-
sess the EAC harmonization. Results showed that
improvements were required in order for the current
EAC processes to meet the vision of harmonization.
Harmonization will result in quicker access to the
harmonized markets for quality-assured medicines
(Storehagen et al., 2019).
WHO Regulatory Support
The World Health Organization (WHO) offers support
with respect to medicines regulation using three ap-
proaches:
• development of international norms, stand-
ards and guidelines;
• offering of guidance and technical assistance;
• training and collaboration with NMRAs, devel-
opment organizations, and other UN agen-
cies.
Specifically, WHO assesses the NMRAs, provides
guidelines, guidance and manuals, provides training
opportunities on model computerized registration sys-
tem (SIAMED), model web-site, WHO prequalification
of medicines moving in international commerce, inter-
national cooperation and harmonization and during
International Conference of Drug Regulatory Authori-
ties (World Health Organization, 2019).
WHO recognizes the sovereignty of countries’
NMRAs to regulate and control. According to WHO
(2019), expectation of NMRAs structure and func-
tions:
Solid legal basis, realistic objectives, appro-
priate organizational structure, adequate
number of qualified staff, sustainable financ-
ing, access to up-to-date evidence based
technical literature, equipment and infor-
mation, capacity to exert effective market
control. MRAs must be accountable to both
the government and the public and their de-
cision-making processes should be transpar-
ent. Monitoring and evaluation mechanisms
should be built into the regulatory system to
assess attainment of established objectives
(p. 1).
All of the regulatory support provided by WHO is to
ensure effective regulation. Effective regulation in-
volves the following among others: ensuring quality,
safety and efficacy of medicines, good manufacturing
practice, distribution, storage of medicines, ensuring
rational use of medicines by patients and prescribers,
enforcement, detection of illegal manufacturing, ade-
quate sanction, fair promotion and advertisement that
is geared towards allowing rational use of medicines
and observing Good Regulatory Practice (World
Health Organization, 2019).
EAC-MRH
The East Africa Community Medicines Regulatory
Harmonization (EAC-MRH) Project is the first regional
bloc MRH of the African Medicines Regulatory Har-
monization Program and Global Medicines Regula-
tory Harmonization Initiative sponsored by technical
and financial partners – AUDA-NEPAD, WHO, World
Bank and the BMGF (BCG, 2017). The EAC Secre-
tariat, together with the NMRAs of the Partner State
of EAC, took this initiative in order to ensure availabil-
ity of quality, safe and efficacious medicines.
Some of the successes recorded at the end of five
years of EAC MRH Project were the development of
harmonized requirements – guidelines, guidance,
manuals and SOPs. The Joint Assessment procedure
approved nine medicines out of 45 applications that
were filed. The median months for obtaining Market-
ing Authorization was reduced to eight months from
14. Some of the things that were not achieved within
the five years included harmonization of the IMS,
meeting of the procedure timelines for the Joint As-
sessment and Good Manufacturing Practice (GMP)
(BCG, 2017). After its assessment, the EAC MRH re-
ceived recommendations for another five years
(2018-2022), in which in short term, it would be re-
quired to continue the MRH for another 6 months, me-
dium term, prove the sustainability and value addition
of the MRH for 18 months and in the long term, estab-
lish a semi-autonomous East Africa Healthcare Prod-
ucts Agency – EAHCPA and mutual agreement
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The ZaZiBoNa, meaning Zambia, Zimbabwe, Bot-
swana and Namibia, in the Southern African Develop-
ment Community (SADC) region was initiated in 2013
to jointly assess medicine dossiers submitted in these
countries. The ZaZiBoNa approach reduced the me-
dian timeline from dossier submissions to national
Marketing Authorization to eight months, through Col-
laborative Registration Procedure (CRP) (Ndomondo-
Sigonda et al., 2017). At its 12th Session reported in
the NEPAD newsletter, six out of 13 dossiers as-
sessed were recommended for approval (NEPAD,
2016).
ECOWAS
The Economic Community of West African States
(ECOWAS) is the regional body of the fifteen coun-
tries in West Africa (Benin, Burkina Faso, Cabo
Verde, Cote d’Ivoire, Ghana, Guinea, Guinea Bissau,
Liberia, Mali, Niger, Nigeria, Senegal, Sierra Leone,
the Gambia and Togo) (ECOWAS, n.d.) to promote
economic integration. It was established on May 25,
1978 by a treaty, termed – Lagos Treaty (ECOWAS,
n.d.). The integrated economic activities, as envis-
aged, revolved around, but were not limited to indus-
try, transport, telecommunications, energy, agricul-
ture, natural resources, commerce, monetary and fi-
nancial issues, and social as well as cultural matters
(ECOWAS, n.d.). Among the specialized Agencies of
ECOWAS was the West African Health Organization
(WAHO).
WAHO
WAHO was created by the Protocol A/P2/7/87 on July
9, 1987 and signed in Abuja, Nigeria by the Heads of
State and government to ensure coordination of re-
gional health interventions within the ECOWAS region
(WAHO, n.d.-a, n.d.-b; West African Health Organiza-
tion, n.d.). Aligning with the desire of the ECOWAS
Government to move from being a ‘Community of
State’ to a ‘Community of the People’ by 2020, WAHO
made every effort to produce high impact and cost-
effective health interventions that would be felt by
members of ECOWAS community and international
community as proactive regional health integration in-
strument ([WAHO, n.d.). According to West African
Health Organization, the new Thematic Areas that
they were focusing on in the time of recurring epidem-
ics and scarcity of resources included:
1. maternal, child & adolescent health quality
standards & centres of excellence
2. pharmaceuticals (medicines & vaccines)
3. prevention & control of communicable and
non-communicable diseases)
4. health Information
WAHO also ensured capacity building, youth devel-
opment, strengthened networks and sustainability
during the implementation of any of the thematic ar-
eas (WAHO, n.d.).
The big picture of pharmaceuticals (medicines, vac-
cines and other health products), their manufacture,
regulation and key related activities for 2014-2019
were described in the ECOWAS Regional Pharma-
ceutical Plan (ERPP). This was the consolidated ap-
proach (Ossei-Yeboah-Agyeman, 2017) that had
been accepted by the international community, As-
sembly of Health Ministers, Heads of State and Gov-
ernment of ECOWAS Member State (Ossei-Yeboah-
Agyeman, 2017).
ECOWAS Regional Pharmaceutical Plan ERPP
2016-2020
The ERPP (ECOWAS, 2014) had eight objectives
(Ossei-Yeboah-Agyeman, 2017), which were the fol-
lowing:
i. strengthen the National Medicines Regula-
tory Authorities (NMRAs) regulatory capacity
and quality infrastructure in the ECOWAS re-
gion to achieve International Certification and
designation as Regional Centers of Excel-
lence by the year 2018;
ii. strengthen local production of pharmaceuti-
cals in the region;
iii. improve and strengthen the governance of
the pharmaceutical systems;
iv. promote and support competitive and efficient
regional pharmaceutical manufacturing to en-
sure the supply of essential medicines pro-
duced in the region; support provision to
pharmaceutical manufacturing in order to
achieve international certification;
v. reduce incidence of Substandard and Falsi-
fied (SF) medical products in the ECOWAS
region by 75%;
vi. establish of a regional medicines regulatory
Agency;
vii. facilitate of the incorporation of ECOWAS pol-
icies on TRIPs flexibilities into national laws;
viii. formulation and implementation of policies
that will promote innovation, research and de-
velopment into pharmaceuticals and medici-
nal products within the ECOWAS region as
 
        
    
 
   
     
          
      
         
        
     
       
          
        
         
        
     
         
        
      
       
         
      
       
        
      
        
      
       
        
        
       
        
    
     
 
       
        
 
        
         
        
        
     
        
         
        
        
      
        
          
       
         
       
       
       
     
 
          
       
         
           
       
      
       
        
        
       
       
        
        
 
   
       
       
       
       
         
       
          
         
         
       
      
        
         
     
         
       
   
       
     
    
      
    
  
     
       
      
       
    
        
       
        
       
      
        
9
well as establish a competitive grant in the
ECOWAS region (WAHO, 2014).
NMRAs in ECOWAS
There were National Medicines Regulatory Authori-
ties (NMRAs) in each of the 15 Member States of
ECOWAS. They were, however, different in function-
ality and system due to their economic and political
heritages. Prior to coming together under the West Af-
rican Medicines Regulatory Harmonization initiative,
the eight French countries had regulatory systems
similar to that of France, the five English countries had
a different system to that and two Portuguese speak-
ing countries had a different system. These were all
at different levels of development in terms of auton-
omy, governance, system and structure.
However, in 2014, with the support of the technical
and financial partners such as the New Partnership
for Africa’s Development (NEPAD), World Health Or-
ganization, World Bank, Bill and Melinda Gates Foun-
dation, the two main regional bodies in West Africa
(Union Economie Monetaire Ouest African [UEMOA]
and West African Health Organization under the lead-
ership of the ECOWAS), came together to integrate
their medicines regulation harmonization systems and
made it more efficient because they agreed to estab-
lish the West African Medicines Regulatory Harmoni-
zation (WA-MRH) Project. Also established were a
Steering Committee comprising the heads of the 15
NMRAs, to provide direction and the Experts Working
Groups which were to provide technical assistance
and help develop technical documents in the seven
major regulatory domains (Ossei-Yeboah-Agyeman,
2017; World Bank, 2012).
Regulatory Functions of the NMRAs in ECOWAS
from data obtained from 2005, 2010 and 2017 re-
ports
i. Authority and Legal Forms of the NMRAs
Ndomodo-Sigonda et al. (2017) reported 53 out of 54
countries in the sub-Saharan Africa had NMRAs or
administrative entities that carried out some form of
regulatory functions. Some were semi-autonomous,
meaning they have some levels of independence from
the Ministry of Health (MoH) in carrying out their reg-
ulatory functions; while others are Departments in the
Ministries of Health. The mandate of some NMRAs
covered medicines, food, medical devices or cosmet-
ics, while others were medicines and medical devices
only. The funding of the NMRAs varied – some were
fully funded by the government and therefore, re-
quired to remit all revenue generated to the single
government treasury; others were permitted by the
government to retain some percentage of revenue
generated for day-to-day running of the organization
(Ndomondo-Sigonda et al., 2017).
In most of those NMRAs that were departments in the
Ministry of Health, the core regulatory functions ex-
pected of an NMRA were usually carried out by differ-
ent departments in or out of the Ministry of Health. In
West Africa, there were examples of the semi-auton-
omous and non-autonomous NMRAs, with core regu-
latory functions being carried out by several depart-
ments of the Ministry of Health. However, throughout
the years, there was greater awareness among the
government of ECOWAS Members State to grant au-
tonomy or semi-autonomous status to their NMRAs
and the increasing number of NMRAs were gradually
moving towards becoming an Agency (WAHO, 2018).
ii. Marketing Authorization
The process of registration of medicines (Marketing
Authorization) was considered one of the core regula-
tory functions of NMRAs (Ndomondo-Sigonda et al.,
2017; WHO, 2010). WHO’s report presented the re-
sults of the assessments of regulatory systems of 26
sub-Saharan African countries (24 belonging to the
WHO AFRO region of which eight NMRAs were of the
West Africa region, six French speaking and two were
English speaking) over the last eight years, to identify
regulatory gaps and suggest priority activities to
strengthen regulatory capacity (WHO, 2010). The re-
port recognized that NMRAs must meet six major re-
quirements in order to be able to assess applications
for marketing authorization. They are:
i. legal basis, giving the NMRA the power to
grant, renew, vary, suspend and withdraw of
marketing authorization;
ii. guidelines for applicants regarding the details
of technical requirements for medicines dos-
sier to be assessed;
iii. standardized operating procedures to assess
submission, communicate and publish out-
comes;
iv. adequate expert assessors;
v. secure storage, retrieval and exchange of
data with other regulatory departments;
vi. Mechanisms to consider the decisions of
stringent NMRAs (WHO, 2010).
The scenario in West Africa gradually started to re-
semble the proposed structure by the WHO, espe-
cially with the support of technical and financial part-
ners who sponsored the West African Medicines Har-
monization Project. The project was officially
launched in November 2017 and contributed to the
 
       
        
   
 
     
      
      
        
      
        
        
       
          
       
      
         
       
       
       
      
        
        
        
     
    
      
       
    
       
       
        
       
       
       
 
 
     
 
       
      
        
     
         
        
       
        
        
       
       
    
 
     
         
        
         
      
       
        
      
       
      
         
        
         
        
     




    
       
        
       
         
      
       
      
      
         
   
    
  
         
     
      
   
     
       
        
      
        
         
      
     
      
      
          
        
        




development of both regional and national capacities
in the domain of medicines dossier evaluation and
registration (WA-MRH-WAHO, 2017).
iii. Good Manufacturing Practice (GMP)
Good Manufacturing Practice inspection is conducted
in pharmaceutical facilities to ensure that manufactur-
ing activities carried out in such facilities were accord-
ing to recognized international standards (WHO,
2010). The WHO’s report of 2010 demonstrated a
system to carry out inspections existed in most
NMRAs that were assessed. However, this activity
was not carried out by the NMRAs in some countries.
Sometimes the inspection was done in conjunction
with another government institution (WHO, 2010).
All member states in West Africa participated in the
WA-MRH Project. The Experts Working Group on
GMP established in the WA-MRH Project, developed
guidelines, guidance and SOPs in accordance to
WHO international GMP Guidelines. There was ongo-
ing joint inspection, which included training among the
experts and other Members State. The EAC-MRH has
a similar group as the WA-MRH which developed har-
monized guidelines on GMP inspection (Ndomondo-
Sigonda et al., 2017).
The West African Health Organization (WAHO) work-
ing with the United Nations Industrial Development
Organization (UNIDO), assessed manufacturing facil-
ities and trained both NMRAs inspectors and manu-
facturers in Members State of ECOWAS. GMP
roadmaps were developed for the region and nations
with or without manufacturing sites. They also devel-
oped Corrective Action and Preventive Action (CAPA)
for all manufacturers that were assessed (Ekeigwe,
2019).
iv. Quality Control of Medicines
The United States Pharmacopoeia (USP) worked in
collaboration with AUDA-NEPAD, WAHO and other
Regional blocs to establish the Network of Official
Medicines Control Laboratories (NOMCOL) for labor-
atories within Africa and its regional blocs. WAHO, in
conjunction with USP, carried out an assessment of
the laboratories in West Africa and proposed recom-
mendations that would strengthen the capacity of the
laboratories in the region with respect to purchase
and maintenance of laboratory equipment, training of
human resource and purchase of reference standards
to help with testing.
v. Quality Management Systems (QMS)
The WHO report of the rapid assessment of 26
NMRAs in sub-Saharan Africa revealed that as of
2010, none of the NMRAs had established a robust
and comprehensive Quality Management System to
support their regulatory functions (WHO, 2010).
According to the 2017 report of Ndomodo-Sigonda et
al., the East African Community Medicines Regula-
tory, harmonization was able to develop harmonized
guidelines on Quality Management System (QMS).
The QMS of NMRAs in West Africa were assessed
between 2015 and 2017 and, based on observed
gaps, developed the roadmaps to be followed by each
Member State to arrive at attaining ISO 9001:2015
and Pharmaceutical Inspection Cooperation Scheme
(PICS) (Ossei-Yeboah-Agyeman, 2018; WAHO,
2018).
vi. Information Management System
The Information Management Systems (IMS) in the
NMRAs in West Africa were upgraded since the WA-
MRH Project. Harmonized guidelines and SOPs were
developed. A handful of NMRAs in the West African
region had functional websites where regulatory infor-
mation such as registration status of medicines, li-
censed manufacturing sites and information were
shared with relevant stakeholders. The development
of some of these websites were sponsored by the
WA-MRH project.
vii. Harmonization and International Coopera-
tion
All NMRAs in West Africa were participating in the
West Africa Medicines Regulatory Harmonization
Project (WA-MRH), which is discussed below:
WA-MRH Project
The West African Medicines Regulatory Harmoniza-
tion Project (WA-MRH) launched in November 2017
with the aim to ensure availability of quality medi-
cines through harmonization of regulatory systems
that will be effective and transparent. The WA-MRH
Project had an initial focus on four domains of medi-
cines regulation, namely: medicines evaluation and
registration, Good Manufacturing Practice (GMP) In-
spection, Quality Management System (QMS) and
Information Management System (IMS). These focus
areas were sponsored in the past, for two years, by
the technical and financial partners of the umbrella
program and initiative – AMRH and GMRHI (WHO,








































































   
 
  










Table 1 Summary of timelines, occurrences accomplishments of each time period stated above and their signifi-
cance.





Early History a. Beginning of Regulatory
Inspections and Enforce-
ment in London.
the history of the foundation 
of modern medicines regula-
tion
Beginning of medicines regulation.
b. The Beginning of the Helped establish the standard Standard formulations of medicines
Pharmacopoeia in Flor- formulations of medicines and became possible, several manufac-
ence, Europe. thereby lifted the limit of the
manufacturers of medicines.
turers for one medicines became 
possible and regulatory inspection 
was established.
1540-1865 Further Development to Medi-
cines Regulation in Europe
The accelerated evolution of
regulation of medicines in Eu-
rope.
Commencement of medicines regu-
lation in Europe.
Modern a. United States Food and 
Drug Administration 
(USFDA) 1930-1938.
The formation of the Food 
and Drug Administration from
Bureau of Chemistry in the 
Department of Agriculture;
The creation of new provi-
sions in federal Food, Drug
and Cosmetic (FD&C) Act for
manufacturers to demonstrate 
that a drug was safe before it
could be marketed.
Commencement of medicines regu-
lation in the United States of Amer-
ica.
b. 1975 – Commencement
of Harmonization in Eu-
rope
The idea of harmonization 
was introduced. The Mutual
Recognition Procedure began 
and the Central Procedure to 
ensure a common market for
medicines in Europe;
Collaboration started among 
Japan, the European Union
and the United States of
America to yield International
Conference on Harmonization 
of Technical Requirements for
Registration of Pharmaceuti-
cals for Human Use (ICH)
where dossiers of new and in-
novative medicines would be 
evaluated to ensure quick ac-
cess to the people who
needed them most.
The commencement of the Com-
mon Technical Document (CTD)
used in the International Conference 
on Harmonization of Technical Re-
quirements for Registration of Phar-
maceuticals for Human Use (ICH).
c. 2003 – The Establishment Establishment of the Medi- The UK joined the League of Na-
of the UK Medicines and cines and Healthcare Prod- tions - USA and in Europe, where 
Healthcare Products Reg- ucts Regulatory Agency both medicines and medical devices
ulatory Agency (MHRA) (MHRA) in the United King-
dom (UK).
are housed under one organization.
d. 2005 - Medicines Regula-
tion in Africa
Documentation of the 
strengths, weaknesses, op-
portunities and recommenda-
tions of medicines regulation 
in Africa and development of
a five-year strategic plan for
improvement.
Setting of the first set of strategies
and roadmap for development of
medicines regulation in Africa.
 































































e. 2014, World Health As-
sembly 67.20
Assessment of regulatory ca-
pacity of the NMRAs using 
WHO Global Benchmarking 
Tools (WHO-GBT);
Collaboration of the national
NMRAs to form regional blocs
that will move towards collab-
oration, regulatory conver-
gence , and transparency in 
decision-making;
Development of strong legal
basis and political direction to 
support the regulatory sys-
tems;
Pooling together of resources,
regulatory experts, not re-in-
venting the wheels but adopt-
ing / adapting already devel-
oped technical guidelines and 
guidance;
Strengthening of regulatory
system as a component of ex-
pansion of local and regional
production of quality, safe and 
efficacious medicines (WHO,
2015).
A call of the WHO to Regulatory
System Strengthening for medical
products.
Highlighted the pivotal role of the 
World Health Organization to sup-
port of the establishment and sus-
tainability of an effective regulatory
system in developing countries.




for development of medicines
regulation in the West Africa 
accepted by the ECOWAS
Assembly of Health Ministers,
Heads of State and Govern-
ment and international com-
munity.
ix. Strengthen NMRAs reg-
ulatory capacity and 
quality infrastructure in
the ECOWAS region to 
achieve International
Certification and desig-
nation as Regional Cen-
ters of Excellence;
x. strengthen local produc-
tion of pharmaceuticals
in the region;
xi. improve and strengthen 
the governance of the 
pharmaceutical systems;
xii. promote and support
competitive and efficient
regional pharmaceutical
manufacturing to ensure 
the supply of essential
medicines produced in 
the region;
The involvement of 15 Members
States in West African Medicines
Regulatory Harmonization (WA-
MRH) Project with the support to 
with the support of technical and fi-
nancial partners;
The ECOWAS harmonized Com-


























reduce incidence of Sub-
standard and Falsified 
(SF) medical products in 
the ECOWAS region by
75%;




tion of ECOWAS policies
on TRIPs flexibilities into 
national laws;
Formulation and imple-





within the ECOWAS re-
gion as well as establish 
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Justification
The literature revealed that there was a scarcity of in-
formation on human resources in the arena of medi-
cines regulation in sub-Saharan Africa (SSA)
(Ndomondo-Sigonda et al., 2017). This scarcity of in-
formation was also found in all the domains of medi-
cines regulation in sub-Saharan Africa.
The information on medicines regulation were not
easily found. The published information on medicines
regulation in ECOWAS region was no longer current.
Additionally, the available information was no longer
consistent with the current realities in the NMRAs.
Much has changed, but the published information on
medicines regulation in Africa are still those that were
presented in 2005, 2010 and 2017. There was also a
need to know the trend, how the region fared since
the 2005 meeting of the heads of African medicines
regulatory authorities.
Objective
This research paper had three main objectives:
1. It aimed to put together a story of
medicines regulation in Africa.
2. It compared the data found in 2005,
2010 and 2017 research papers and reports
and attempted to discover any trend (increas-
ing or decreasing) in the state of medicines
regulation in West Africa.
3. The results of the comparison re-
vealed the existence of any gaps, proposed
solution(s) or available opportunities that




A literature map was prepared to provide the frame-
work and scope that guided the search and review of
relevant literature.
The search of the literature was carried out according
to the literature map, which is in a hierarchical struc-
ture, from top to bottom, using the dates, starting at
the earliest time when events occurred in medicines
regulation to the latest time, leading to the bottom with
the proposed study. The selected literature was sum-
marized, building bridges between related topics in
Medicines Regulation and identifying central issues of
previous scholarly work written on medicines regula-
tion across the globe, in Africa and more specifically,
West Africa.
Choice of Reference Research Paper and Report
During the literature search and review, some reports
and research papers stood out because they had in-
formation on the assessment that was done on medi-
cines regulatory systems and structure in sub-Sa-
haran Africa and their outcomes at specific times in
the past. There was one 2005 report of the First Afri-
can Medicines Regulatory Authorities Conference,
which had information on the state of the regulatory
systems and structure in Africa as of 2005, which pro-
posed a strategic plan (2006-2010) with recommen-
dations and next steps going forward. This, then, be-
came a reference to measure subsequent medicines
regulatory plans and activities in the continent.
Another important document that was used was the
report of the rapid assessment of 26 NMRAs in sub-
Saharan Africa that was carried out by the World
Health Organization (WHO) between 2006-2010. This
became another point of reference to compare what
was found in 2005 to what WHO reported in their 2010
published report.
A third report, a paper by Ndomondo-Sigonda et al.
(2017) compiled the state of medicines regulation in
all the NMRAs in the sub-Saharan Africa as of 2016.
This report described the trend of medicines regula-
tion since 2005, when the regulatory authorities first
met.
The following systems and structure of medicine reg-
ulation were the focus of the comparison: authority
and legal forms of the NMRAs, existence of Marketing
Authorization, conduct of Good Manufacturing Prac-
tice inspection, harmonization and international coop-
eration, existence of Quality Management System, In-
formation Management System and Quality Control
Laboratory(s). These seven areas were chosen as the
focus because their existence in a medicines regula-
tory system gave an idea of the maturity of the NMRA.
During the courses of this study, several other reports
and papers were consulted in order to obtain specific
information on these seven focus areas; some of
which were the reports of countries under the WA-
MRH Project, Project Papers of World Bank funded
Projects, reports of WA-MRH and SWEDD Projects
and reports of other activities as were deemed fit. Cer-
tain information on Quality Management Systems of
 
       
   
 
         
 
          
         
       
        
        
         
         
       
          
        
       
          
         
          
    
     
         
        
        
         
        
          
        
        
    
         
       
        
         
          
        
          
          
        
        
         
      
 
     
         
        
         
          
     
     
      
        
        
      
          
        
         
 
 
    
 
        
        
 
 
          
       
   
         
     
         
        
       
 
        
         
      
      
  
         
        
         
      
         
         
      
        
       
      
         
         
    
        
      
       
         
      
       
  
          
        
        
    
16
the NMRAs were obtained from reports of assess-
ments and surveys.
Choice of Countries and Collation of Data in the
Research
The countries that were chosen for a closer look from
the 2005, 2010 and 2017 reports were the fifteen
Members States of ECOWAS. The data obtained
from the Strategic Plan 2006-2010 were mined from
the report of the First African Medicines Regulatory
Conference and were regarded as the 2005 data. The
data from the report of the assessment of regulatory
systems of twenty-six countries that the WHO as-
sessed were mined from the report and were taken as
the 2010 data. The data on medicines regulatory re-
port of Ndomondo-Sigonda (2017) were mined and
used as the 2017 data. The data that were obtained
from the 2005 Strategic Plan were used as the base-
line to compare the data obtained from the reports of
2010 and 2017.
Analysis of the report obtained
The data obtained from the 2005, 2010 and 2017 re-
ports were anayzed. In order to quantify the infor-
mation obtained from the reports, all responses that
had a “Yes” or positive inclinations were assigned “1,”
while the “No” or negative inclination responses were
awarded a “0.” In any situation where a response was
“Yes/No,” “0.5” was assigned. The countries in which
the reports had no information on the regulatory fea-
ture were assigned nothing.
The sum of these numbers obtained by the 15 coun-
tries per regulatory feature were taken and percent-
ages calculated. The information from the 2005 report
was used as the reference for this study. 6.67% de-
rived from one over fifteen was assigned as the least
percentage of the chosen regulatory features for all
the 15 ECOWAS countries. A zero (0) could not be
assigned to that year even though, the report did not
have information on specific countries’ NMRAs, it was
the year that the regulatory problems were identified,
captured in a report and solutions were proposed in
form of a strategic plan.
Advantages of the research work
This study highlights the trends that are in medicines
regulatory systems of the 15 NMRAs in ECOWAS re-
gion from the data gathered from 2005, 2010 and
2017. The trend that was revealed by this study will
demonstrate to stakeholders (manufacturers, donor
partners, researchers, policy makers, WAHO man-
agement) whether medicines regulated by the
NMRAs in the region were progressing. This research
also concluded on how the NMRAs have matured ac-
cording to pre-determined expectations. In future
work, this study with its methodology could be used to
understudy the remaining core regulatory areas in the
NMRAs to allow for discovery and filling of existing
gaps.
3. RESULTS AND DISCUSSION
The results obtained from the comparisons of 2005,
2010 and 2017 data revealed the following major
points:
• None of the papers had information on all the
Members State of ECOWAS as demonstrated by
Tables 1, A3-A9.
• The three papers used for comparison did not
measure the same parameter/indicators. One pa-
per measured some set of indicators and left out
one or more, while the other papers measured
other indicators, hence empty spaces in Tables 3-
9.
• Information on core regulatory features that was
not provided in the paper was unavailable on the
websites of NMRAs, various reports, national
government websites, WHO websites and African
Union website.
• Another reason why some of the Members States
in ECOWAS were omitted or not measured could
have been due to the sampling size per regional
blocs and/or inclusion – exclusion criteria.
• The comparison of the data obtained in 2005,
2010 and 2017 showed an increasing trend in the
number of NMRAS that became autonomous
over the years – 2005 (6.67%); 2010 (13.33%)
and 2017 (26.67%). This demonstrated that the
governments of countries in ECOWAS were be-
coming more aware of the need to grant some
form of independence to their NMRAs in order to
have unhindered/unrestricted judgement of med-
icines with respect to quality, safety and efficacy.
• Concerning Marketing Authorization, the 2010
and 2017 reports had varying information. There
are some countries that the 2010 report said they
have NMRAs that grant Marketing Authorization
(MA), which the 2017 report said were unavaila-
ble.
• This led to the fluctuating trend that is observed
by the following percentage when the 2005, 2010
and 2017 were compared – 2005 (6.67%), 2010
(53.33%) and 2017 (33.33%).
 
        
        
       
        
        
        
        
         
    
      
       
        
        
       
 
       
        
      
      
    
         
        
       
 
         
      
        
      
         
  
       
        
        
         
        
 
       
        
         
       
    
       
        
       
        
        
     
      
       
        
          
          
         
       
 
       
          
       
      
         
       
        
     




• The variation observed in the information derived
from the countries and NMRAs’ data may have
resulted from the difference in the methodology
used to derive the 2005 and 2010 data.
• The 2010 report explained that countries were
visited in order to obtain or confirm the infor-
mation, while the methodology used in the 2017
was a search of information on the NMRAs’ and
countries’ websites and reports.
• Regarding conduct of Good Manufacturing Prac-
tice (GMP) by the NMRAs or another body/insti-
tution in the countries, there was an increasing
trend in the number of NMRAs conducting GMP
inspection, 2005 (6.67%), 2010 (20%) and 2017
(40%).
• The 2010 report specified that regulatory inspec-
tion was being done in some countries, by an-
other entirely different government institution; or
the responsibility for regulatory inspection was
shared with such institution.
• The 2017 report did not specify whether the reg-
ulatory GMP inspection was done solely by the
NMRAs or was shared with other governmental
institutions.
• The comparison of the 2005, 2007 and 2010 re-
ports, regarding Quality Control of Medicines,
showed an increasing trend in the number of
countries that were testing medicines for declara-
tion of quality – 2005 (6.67%); 2010 (20%) and
2017 (53.33%).
• The Quality Management System (QMS) showed
an increasing trend (Appendix VI) in the number
of NMRAs with QMS, 2005 (6.67%); 2010 (10%)
and 2017 (26.67%) despite that the report of 2017
had “unavailable” as information for most of the
NMRAs.
• Information Management System (IMS) was a
regulatory feature not captured in the 2017 report,
but was captured by 2010 report. There is an in-
creasing trend (Appendix VII) observed – 2005
(6.67%) and 2010 (20%).
• The aspect of Harmonization and International
Cooperation was not reported in one of the re-
ports (2010). However, a steep increase was ob-
served between the two reports that reported this
regulatory feature. There was an increase in the
number of countries/NMRAs involved in harmoni-
zation and international cooperation over the
years – 2005 (6.67%) and 2017 (86.67%).
• Overall, from the results obtained by comparing
the data from the 2005, 2010 and 2017 reports, it
can be said that there was increase in the number
of the NMRAs that have progressed in the seven
regulatory features that were measured in this pa-
per.
• Literature showed the beginning of medicines
regulation as early as 200 BC – 100 AD. The be-
ginning of the UK’s Medicines and Healthcare
Products Regulatory Agency (MHRA) in 2003
was found and the report of the First African Med-
icines Regulatory Conference that took place in
Addis Ababa in 2005, where the Mother-Plan (a
Strategic Plan 2005-2010) for Medicines Regula-
tion in Africa was formed was discovered.
 
 
                 
 
           
           
       
         
       
       
       
        





        
         
    
       
       
       
        
       
     
      
       
          
      
       
       
      
  
        
        
          
          
        
         
         
     
         
    
          
          
         




   
 








Table 2 Summary of Regulatory Features of the MRAs in ECOWAS derived from the 2005, 2017 and 2019 Re-
ports.
S/No Some Features of a Medicines Regulatory Authority 2005 2010 2017
Authority and Legal Form of the NMRAs 6.67 13.33 26.67
Marketing Authorization 6.67 53.33 33.33
Good Manufacturing practice Inspection 6.67 20 40
Quality Control Laboratories 6.67 20 53.33
Quality Management System 6.67 10 26.67
Information Management System 6.67 20 -
Harmonization and International Cooperation 6.67 - 86.67




4. Quality Control… 
3. Good… 
2. Marketing… 
1. Authority and… 
Summary of Regulatory Features of the 
MRAs in ECOWAS derived from the 2005,
2017 and 2019 Reports 
2005 2010 2017 
Figure 1 Percentage information captured on some core
regulatory features of the NMRAs in ECOWAS in the
2005, 2010, 2017 Reports.
The literature post-2005 regarding the regulation of
medicines in Africa, the Regional Economic Blocs re-
vealed that the ongoing, vibrant activities on regula-
tory harmonization in the RECs, development of the
African Union Model Law, development of in-country
medicines policies, regulation and legislation, estab-
lishment of Regulatory Centres of Excellence
(RCOREs), were all recommended activities from the
2005 Mother Plan made by the Heads of the NMRAs
and stakeholders. The contributions of various stake-
holders of medicines regulation such as WHO, Strin-
gent Regulatory Authorities (SRAs) were in tandem
with the Mother-Plan over the years.
Future Study
Future study would consider 2019 data on medicines
regulation in Africa/West Africa and compare it with
the results of 2005, 2010 and 2017 to trend progress
and determine if any had been made. The 2019 data
that would be collected would served as baseline
data, which would be used to start the assessment of
the other core regulatory functions carried out by the
NMRAs in ECOWAS going forward.
A copy of the proposed questionnaire is in Appendix
1 of this paper.
Another future focus of this study would to carry out
qualitative study which will allow to go into the details
of these identified systems and structures in order to
measure their strength and quality.
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4. CONCLUSION
In conclusion, the comparison of the 2005, 2010 and
2017 reports showed that there was missing infor-
mation on the regulatory features of countries that
were studied. The indicators measured in the different
reports compared, were, in some cases, not the
same, maybe due to the differences in objective of
studies, exclusion and inclusion criteria which are pe-
culiar to studies and the methodology used. Overall,
the comparison of the report revealed that there was
cumulative progress in the regulatory features meas-
ured in Members State of ECOWAS over the years
2005 through 2017.
The essence of the finding of the study is that Africa
and its regional blocs’, especially West Africa’s, med-
icines regulatory landscape changed. The develop-
ment of Medicines Regulation has made significant
progress. The contributions to improvement in the
West Africa region have been gradual but sure.
5. RECOMMENDATIONS FOR NEXT
STEPS (OPPORTUNITIES)
The recommendations and next steps that are spe-
cific to this research follows:
• Keep updating unifying regional and national indi-
cators on which the Monitoring and Evaluation Of-
ficers at the regional and national levels should be
trained and re-trained. The Africa Union Develop-
ment Agency – New Partnership for Africa’s De-
velopment (AUDA-NEPAD), RECs with the col-
laboration of WHO, unified the indicators that are
now being measured in the regional blocs. The
training of West African regional and national
Monitoring and Evaluation (M&E) officers on the
uniformed AMRH M&E Data Collection Tool
(AUDA-NEPAD, 2019b) was conducted in Abid-
jan, Cote d’Ivoire in 2019 (AUDA-NEPAD,
2019a). The process of development of uniform
indicators was completed in 2017, piloted in 2018
in the regional blocs with accompanying training
and collection of data in 2019.
• Ensure that each of the NMRAs in West Africa
has functional and robust Information Manage-
ment System (IMS) exemplified by a functional
website linked to the government websites. Fur-
ther, ensure that the regulatory information and
the vital signs of regulatory authorities are obvi-
ous and available to interested stakeholders.
• The regional, continental institutions, technical
and financial development partners (WAHO,
AUDA-NEPAD, WHO, World Bank, BMGF)
should ensure continued advocacies towards the
governments of ECOWAS Members State for se-
curing adequate authority and autonomous legal
status for the NMRAs in the West Africa region.
• Continue to advocate that all regulatory functions
are carried out by only the NMRAs. For example,
the Good Manufacturing Practice inspections are
carried out solely by the NMRAs of the countries
and not shared among governmental institutions.
• With respect to the Quality Control laboratories,
WAHO and the AUDA-NEPAD should keep up
the advocacies to government of countries to fi-
nance their National Medicines Control Laborato-
ries (NMQCLs). These NMQCLs are faced with
numerous challenges ranging from inadequate
equipment, maintenance of them, reference
agents and qualitative and quantitative human re-
sources. WAHO, USP and WHO are working in
collaboration directly with the NMQCLs to ensure
that these needs are met (Ekeigwe, 2019;
WAHO-USP, 2019).
• All the NMRAs in ECOWAS are actually partici-
pating the West African Medicines Regulatory
Harmonization (WA-MRH) Project and have ben-
efited with respect to strengthening capacities in
Dossier evaluation, GMP inspection, QMS, IMS
(WAHO, 2020; World Bank, 2012).
• The NMRAs are further encouraged to continue
to explore the opportunities available in the re-
gional and continental medicines regulatory initi-
atives (AMRH and WA-MRH) with regards to In-
formation Management System and Harmoniza-
tion / international cooperation.
This recommendations from this research encour-
aged all stakeholders to take steps towards complete
implementation of the interventions proposed in the
2005 Mother plan and subsequent continental and re-
gional plans. The recommendations also encourage
Competent Authorities, responsible bodies, organiza-
tions and institutions to cooperate and collaborate,
specifically to review the Mother plan, and propose
another Strategic Plan (5-10 year) for medicines reg-
ulation in Africa.
• The regional and national regulatory authorities
should make use of available opportunities in the
continent and region to strengthen their regulatory
capacities. Some of which are the opportunities
available in the proposed Africa Medicines
Agency, Africa Medicines Regulatory Harmoniza-
tion (AMRH) and the regional harmonization initi-
atives. Others include harmonized guidelines,
guidance and procedures for the Joint Assess-
ment (JA) of medicines dossiers procedure, joint
inspections, Quality Management System which
provide minimum acceptable standards. There is
also the Information Management System for
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sharing and exchanging of information among
Members State (Ndomondo-Sigonda et al.,
2017).
Additional opportunities that should be seized are the
pool of regional/continental experts, the Regional
Centre of Regulatory Excellence (RCOREs) that en-
sure sustainable training in the regions/continent, Net-
work of Medicines Control Laboratories (NOMCOLs),
the alignment of Africa Vaccines Regulatory Forum
(AVAREF) with AMRH, WHO Collaborative Registra-
tion Procedure.
The results of this work demonstrate value for similar
reviews by other regional blocs to demonstrate the
progress that their regions have made with respect to
the Strategic Plan of 2005, WHO assessment report
of 2010 and other published literature. Members State
in ECOWAS that are still lagging behind in one regu-
latory function, structure and system should continue
to make efforts, whether with advocacies with their
governments through the specialized regional body
on health (WAHO) or building of capacities using op-
portunities of their governments’ subventions in order
to ensure sustainability or provisions made by re-
gional, continental and international initiatives. There
will be a need to establish a list of the expectations for
the coming years or to develop another plan for med-
icines regulation in Africa, teased from African Union
Agenda 2063 or other continental, plan that will be
monitored and evaluated to demonstrate progress
made.
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Proposed questionnaire for review towards the 2019-2020 survey
Table A2 A sample of one of the proposed Questionnaires to gather information on the systems and structure for granting





Information on the System of Registration of Medicines in NMRA in ECOWAS
Data Collection (2019)
S/NO Data Collection Requirements (What needs to be measured?) Response Remarks
(Yes / Non) (Evidence)
Is NMRA using the Common Technical Documents (CTD) format as the requirement for
submission of medicines dossiers for Registration in 2019?
Is NMRA doing paper submission of registration applications in 2019?
Is NMRA doing paper submission of medicines dossiers in 2019?
Is NMRA doing on-line submission of registration applications in 2019? (Evidence: URL)
Is NMRA doing on-line submission of medicines dossiers in 2019? (Evidence: URL)
Does NMRA has on-line tracking system for applications under-going registration in 2019?
(Evidence: URL)
Do individuals have to come in person to track the applications under-going registration in
2019?
Does your NMRA have Guidelines, Standard Operating Procedure (SOPs) and Guidance
for registration of medicines in 2019? (Evidence)
Does your NMRA have National Medicines Policy (NMP) in 2019? (Evidence)
Does your NMRA have established timelines for registration of medicines in 2019? (Evi-
dence)
Does your NMRAs have documented timelines in 2019? (Evidence)
Does your NMRA have systematic tracking in 2019? (Evidence)
Does your NMRA have electronic notification when registration is completed in 2019?
Does your NMRAs post list of registered medicines on on-line (website of NMRA) in 2019?
(Evidence: URL).
Does your NMRA have a paper publication of registered medicines in 2019?
 
              
        
                 
       
               
               
             
                
         
               
           
               
       
              
    
              
     
            
            
                   
                
                















Does your NMRA have paper notification when registration of medicines is completed in
2019? (Evidence: Sample of the letter).
Do applicants have to come in person to be informed of the completion of the registration
of their products in 2019?
Does your NMRA registers medicines less than 100 days in 2019?
Does your NMRA register medicines between 100 – 200 days in 2019?
Does your NMRA register medicines between 200-365 days in 2019?
How long does it take before Registration Certificates are ready after the approval of the
Registration Committee (Median / Average time)?
Does your NMRA have backlogs of Registration Certificates to produce in 2019?
How many registration officers have your NMRAs?
How many of the registration officers have Bachelor of Pharmacy, B.Sc. level in Chemistry
and other related sciences?
How many of the registration officers have Master’s Degree in Pharmaceutical Science or
related sciences?
How many of the registration officers have Ph.D. degree in Pharmaceutical Science or
other related sciences?
How many of the registration officers that are female?
What is the Age bracket of the registration officers?
What is the average number of years they have worked in the registration Department / Di-
rectorate?
What is the average number of years they got employed in the NMRAs?
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APPENDIX B:
Tables 3 - 9 comparing the data from 2005, 2010 and 2017 reports
Table A3 Comparison of 2005, 2010 and 2017 data on Authority and Legal Forms of NMRAs in ECOWAS.

















Problem to be ad-
dressed inappropri-
ate legal status of
national medicines
regulatory authori-
ties to carry out their
regulatory functions
Status at Year Point (Autonomous =1, Not Autonomous = 0)
Y/N
2010 (1/0) U=0 2017
Dept. within MoH 0 Dept. within MoH
Dept. within MoH 0 Dept. within MoH
U 0 Autonomous
Dept. within MoH 0 Dept. within MoH
Autonomous 1 Autonomous
U 0 Dept. within MoH
U 0 Dept. within MoH
U 0 Dept. within MoH
Board under the control of MoH 0 Board under the control of MoH
Dept. within the Min. of Public
Dept within the Min. of Public Health 0 Health
Autonomous 1 Autonomous
Parastatal Agency Parastatal Agency
(+Professional Council (+Professional Council +Enforce-






















Total 1 Total 2 Total 4
% 6.67 % 13.33 % 26.67
Vacant spaces = U = no available information on that parameter in the literature consulted or the regulatory authority was not in exist-
ence or they were not part of the sample size for those studies in the literature.
Table A4 Comparison of data on the existence of Marketing Authorization process in ECOWAS NMRAs in 2005, 2010 and
2017 reports.
2. Marketing Authorization by NMRA
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Country 1 U Yes 1 U 0
Country 2 U Yes 1 Yes 1
Country 3 U U 0 U 0
Country 4 U Yes 1 Yes 1
Country 5 U Yes 1 Yes 1
Country 6 U U 0 U 0
Country 7
Problem to be Addressed
U U 0 U 0
Country 8
Country 9
1. Inadequate human resource.
2. Inadequate legislation and regulation.












Country 10 U Yes 1 U 0
Country 11 U Yes 1 Yes 1
Country 12 U Yes 1 U 0
Country 13 U U 0 Yes 1
Country 14 U U 0 U 0
Country 15 U U 0 U 0
Total 1 Total 8 Total 5
% 6.67 % 53.33 % 33.33
Yes = NMRA grants MA; Vacant spaces = U = no available information on that parameter in the literature consulted or the regulatory
authority was not in existence or they were not part of the sample size for those studies in the literature.
Table A5 Comparison of NMRAs in ECOWAS conducting GMP Inspection as found in the 2005, 2010 and 2017 reports.





2005 ∑U=1 2010 (1/0) 2017
Y/U
(1/0)
Country 1 U No 0 U U
Country 2 U Yes/No 0.5 Yes 1
Country 3 Problem to be Addressed U U U U U
1. Local production firms non-compliant with GMP / MRA not
Country 4 trained in GMP. U Yes/No 0.5 Yes 1
Country 5 U No 0 Yes 1
Country 6 U U U U U
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Country 7 U U U U U
Country 8 U U U U U
Country 9 U Yes/No 0.5 U U
Country 10 U Yes/No 0.5 U U
Country 11 U Yes 1 Yes 1
Country 12 U No 0 Yes 1
Country 13 U U U Yes 1
Country 14 U U U U U
Country 15 U U U U U
Total 1 Total 3 Total 6
% 6.67 % 20 % 40
Yes = NMRA does the inspection; No = Another Institution does the inspection; Yes/No = NMRA and another Institution do the Inspection
Vacant spaces = U = no available information on that parameter in the literature consulted or the regulatory authority was not in exist-
ence or they were not part of the sample size for those studies in the literature.
Table A6 Comparison of NMRAs in ECOWAS in the 2005, 2010, 2017 reports that conduct Quality Control of Medicines.
4. Quality Control of Medicines





Country 1 U No 0 U 0
Country 2 U No 0 Yes 1
Country 3 U U 0 U 0
Country 4 U No 0 Yes 1
Country 5 U No 0 Yes 1
Country 6
Problems to be Addressed
U U 0 U 0
Country 7
Country 8
1. Weak Quality Control (need to re-equip the laboratories;











Country 9 U Yes 1 Yes 1
Country 10 U No 0 U 0
Country 11 U Yes 1 Yes 1
Country 12 U No 1 Yes 1
Country 13 U U 0 Yes 1
 
       
       
       




                      
                      






                 
    






    
       
        
       
        
         
         
          
          
          
          
         
         
          
    
  
 
     
          
          
          
        
















Total 1 Total 3 Total 8
% 6.67 % 20 % 53.33
Yes = NMRA does the Quality Control; No = Another Institution does the Quality Control or it is not done at all.
Vacant spaces = U = no available information on that parameter in the literature consulted or the regulatory authority was not in exist-
ence or they were not part of the sample size for those studies in the literature.
Table A7 Comparison of NMRAs in ECOWAS in the 2005, 2010, 2017 reports with Quality Management System.


















Problem to be Addressed
No information on Quality Management Systems of





















































































Total 1 Total 1.5 Total 4
% 6.67 % 10 % 26.67
 
 
               
                      






                 
          
           
  
     
      
       
    
    
    
  
   
  
 
      
       
      
      
       
       
       
       
      
      
      
       
       
       
       




                 
                      
                
 
 
                  
 
28
Yes = QMS exists; No = QMS does not exist; anything in between = 0.5.
Vacant spaces = U = no available information on that parameter in the literature consulted or the regulatory authority was not in exist-
ence or they were not part of the sample size for those studies in the literature.
Table A8 Comparison of NMRAs in ECOWAS in the 2005, 2010, 2017 reports with Information Management System.
6. Information Management System (functional Websites: share info. with stakeholders)
2005 ∑U=1 2010 2017 ∑U=1
Country 1 U 0 U
Country 2 U No 0 U
Country 3 U U 0 U
Country 4 U No 0 U
Country 5 U Yes 1 U




Problem to be Addressed
1. Weak Information Management System and










No information in the
2017 research paper on
Information Management





Country 10 U No 0 U
Country 11 U Yes 1 U
Country 12 U Yes 1 U
Country 13 U U 0 U
Country 14 U U 0 U
Country 15 U U 0 U
Total 1 Total 3 Total 1
% 6.67 % 20 % 6.67
Yes = functional website; No = No functional website; Yes/No = development of a website is on-going
Vacant spaces = U = no available information on that parameter in the literature consulted or the regulatory authority was not in exist-
ence or they were not part of the sample size for those studies in the literature.
Table A9 Comparison of NMRAs in ECOWAS in the 2005, 2010, 2017 reports engaging in harmonization and international
collaboration.
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7. Harmonization and International Cooperation
2005 2010 2017
Country 1 U U U 0
Country 2 U U Yes 1
Country 3 U U U 0
Country 4 U U Yes 1
Country 5 U U Yes 1




Problem to be Addressed







not captured by the 2010 re-










Country 10 U U Yes 1
Country 11 U U Yes 1
Country 12 U U Yes 1
Country 13 U U Yes 1
Country 14 U U Yes 1
Country 15 U U Yes 1
Total 1 Total 1 Total 13
% 6.67 % 6.67 % 86.67
Yes = participating in harmonization initiative; No = Not participating in harmonization initiative
Vacant spaces = U = no available information on that parameter in the literature consulted or the regulatory authority was not in exist-
ence or they were not part of the sample size for those studies in the literature.
